

SAMPLE WOUND
REQUISITION FORM

Provider Information / Place of Collection

Please attach the following documents with this test order:

- Demographics
- Insurance Information
- Medical Necessity
- SOAP Notes
- Visit History Notes

Patient Information

Failure to fill in information may result in a delay of processing specimens.

Last First
DOB Gender: Male Female
Address:
City: State: Zip:
Race: American Indian or Alaska Native, Black or African American, Hispanic or Latino, Not Hispanic or Latino, Other Race, White, Other
Ethnicity: Hispanic or Latino, Not Hispanic or Latino, Other

Attach Patient Demographics and Insurance Information

Insurance Verified, Self-Pay Form Attached, Medicare, Medicaid, Work Comp, DOI, Self Pay, Client Bill, 3rd Party Insurance
Relationship, Primary Insurance, Member ID, Group ID

Specimen Collection Information

Specimen Collection Type: NAIL CLIPPING, E SWAB
Date: Time: AM PM
Collectors Name:

Place of Collection: OFFICE, LAB, HOME
Out-Patient, Skilled Nursing Facility, Nursing Facility
Self-Referral/ Walk-in

Diagnosis Codes

B35.1 Tinea unguium, B35.3 Tinea pedis, L02.91 Cutaneous abscess, unspecified, A49.9 Bacterial infection, unspecified, L98.9 Disorder of the skin and subcutaneous tissue, unspecified

2311-Wound Infection Panel (E-Swab)

Bacteria Panel 87798, Fungal Panel 87481, Virus Panel 87529, Resistance Markers
ampC, blaACC, blaACT, blaCMY, blaLAT, blaFOX, blaGES, blaVIM/KPC, Cfr, CMY/MOX/DHA, CTX-M_1, CTX-M_2, CTX-M_8_25, CTX-M_9, dfrA1, dfrA5, ermA, ErmB, ErmC, femA, IMP-1, IMP-2, KPC, MCR-1, MecA, MecC, mefA, NDM, OXA-48, OXA-51, PER-1, qnrA, QnrB_1of4, QnrB_2of4, QnrB_3of4, QnrB_4of4, qnrS, SHV, Sul1, Sul2, Tet(M), Tet(S), vanA2, vanB, VEB

2310-Infection Panel (Sterile Cup)

Bacteria Panel 87798, Fungal Panel 87481, Resistance Markers (included in both the and Wound Panels)
ampC, blaACC, blaACT, blaCMY, blaLAT, blaFOX, blaGES, blaVIM/KPC, Cfr, CMY/MOX/DHA, CTX-M_1, CTX-M_2, CTX-M_8_25, CTX-M_9, dfrA1, dfrA5, ermA, ErmB, ErmC, femA, IMP-1, IMP-2, KPC, MCR-1, MecA, MecC, mefA, NDM, OXA-48, OXA-51, PER-1, qnrA, QnrB_1of4, QnrB_2of4, QnrB_3of4, QnrB_4of4, qnrS, SHV, Sul1, Sul2, Tet(M), Tet(S), vanA2, vanB, VEB

Consent for Testing

I hereby assign all rights and benefits under my health plan, and all rights and obligations that I and my dependents have, under my health plan to GenviewDX, its assigned affiliates and authorized representatives for laboratory services furnished to me by GenviewDX. I irrevocably designate, authorize and appoint GenviewDX, or its assigned affiliates and their authorized representatives, as my true and lawful attorney-in-fact for the purpose of submitting my claims, obtain a copy of my health plan document, Summary Plan Description, disclosure, appeal, litigation or other remedies in accordance with the benefits and rights under my health plan and in accordance with federal or state laws. If my health plan fails to abide by my authorization and makes payment directly to me, I agree to endorse the insurance check and forward it to GenviewDX immediately upon receipt. I hereby authorize GenviewDX its assigned affiliates and authorized representatives to contact me or my health Plan/administrator for billing or payment purposes by phone, text message, or email with the contact information that I have provided to GenviewDX, in compliance with federal and state laws. GenviewDX, its assigned affiliates and their authorized representatives may release to my health plan administrator, my employer, and my authorized representative my personal health information for the purpose of procuring payment of GenviewDX and for all the laboratory services. I understand the acceptance of insurance does not relieve me from any responsibility concerning payment for laboratory services and that I am financially responsible for all charges whether they are covered by my insurance.

Patient Signature:
Date:

Physician Information

As part of my antibiotic stewardship policy, I find it medically necessary to rapidly determine and differentiate a viral and/or bacterial infection in order to treat with or without appropriate antibiotics. Having the most accurate and timely data available to me directly guides my treatment and patient management. Empiric treatment and management leads to inappropriate and unnecessary antibiotic use (50% according to the CDC) and delayed diagnosis which can lead to severe consequences. Standard antibody/antigen detection is only available to detect few pathogens and comes with a high false negative rate, relatively lower sensitivity (60-70%) and specificity (80-90%).

In addition, standard antibody/antigen detection requires the infection to be present for days allowing the body to make ample antibodies in order to detect. Qualitative Nucleic Acid Amplification Testing (NAAT) is far superior with sensitivities and specificities > 98% and available to detect many pathogens. In addition, NAAT has built in controls to determine if an adequate patient sample was collected and processed, therefore greatly reducing false negative results. NAAT also includes controls to easily determine a contaminated sample, therefore reducing false positive results.

Physicians Signature:
Date: